Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease.

April 29, 2016 — AtriCure Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.

American Society of Nuclear Cardiology

New this year, the event offers attendees the chance to share questions, ideas and opinions during live sessions, creating a collaborative, educational and unforgettable experience. This new feature of our meeting app provides presenters and attendees with a powerful engagement tool, while keeping anonymity.

Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact with the heart’s contractile machinery to provide mechanical resistance for the beating of the heart.

Konica Minolta introduced the latest version of the Sonimage HS1 compact ultrasound system, enabling improved image quality, streamlined workflow and new cardiac functionality for the point-of-care ultrasound market.

Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for use in a magnetic resonance imaging (MRI) environment.

April 28, 2016 — Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences (ICES) and the Ted Rogers Centre for Heart Research, University Health Network (UHN). The study was published April 18 in the Journal of Clinical Oncology.


 

April 28, 2016 — Abbott and St. Jude Medical Inc. announced a definitive agreement for Abbott to acquire St. Jude Medical. The merger will create a premier medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure as well as a leading position in the high-growth neuromodulation market. St. Jude Medical's strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management complement Abbott's leading positions in coronary intervention and transcatheter mitral repair. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now